Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation

Cancer Research

Volumn 58, Issue 13, 1998, Pages 2777-2783

  Chen, Chiung Tong ^a   Gan, Yuebo ^a   Au, Jessie L S ^a,b   Wientjes, M Guillaume ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; P-GLYCOPROTEIN; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032127380     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gudziak, M. R., and Smith, A. Y. Hormonal therapy for stage D cancer of the prostate. West. J. Med., 160: 351-359, 1994.
2. Oesterling, J., Fuks, Z., Lee, C. T., and Scher, H. I. Cancer of the prostate. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 5, pp. 1322-1386. Philadelphia: Lippincott-Raven Publishers, 1997.
3. Daniel, F., MacLeod, P. M., and Tyrrell, C. J. Megestrol acetate in relapsed carcinoma of the prostate. Br. J. Urol., 65: 275-277, 1990.
4. Matzkin, H., and Soloway, M. S. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. Urology, 40: 78-80, 1992.
5. Perez, C. A., Fair, W. R., and Ihde, D. C. Carcinoma of the prostate. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 3, pp. 1023-1058. Philadelphia: Lippincott, 1989.
6. Dunning, W. F. Prostate cancer in the rat. NCI Monogr., 12: 351-369, 1963.
7. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostate cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-28s1, 1986.
8. Newhall, K. R., Isaacs, J. T., and Wright, G. L., Jr. Dunning rat prostate tumors and cultured cells lines fail to express human prostate carcinoma-associated antigens. Prostate, 17: 317-325, 1990.
9. Vesico, R. A., Redfern, C. H., Nelson, T. J., Ugoretz, S., Stern, P. H., and Hoffman, R. M. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. USA, 84: 5029-5033, 1987.
10. Schroeder, F. H., and Mackensen, S. J. Human prostatic adenoma and carcinoma in cell culture-effects of androgen-free culture medium. Invest. Urol., 12: 176-181, 1974.
11. Mickey, D. D. Growth and differentiation factors in prostatic tissue. In: M. Motta and M. Serio (eds.), Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, pp. 13-47. Bussum, The Netherlands: Medicom, 1988.
12. Robbins, K. T., Connors, K. M., Storniolo, A. M., Hanchett, C., and Hoffman, R. M. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch. Otolaryngol. Head Neck Surg., 120: 288-292, 1994.
13. Furukawa, T., Kubota, T., and Hoffman, R. M. Clinical applications of the histoculture drug response assay. Clin. Cancer Res., 1: 305-311, 1995.
14. Kubota, T., Sasano, N., Abe, O., Nakao, I., Kawamura, E., Saito, T., Endo, M., Kimura, K., Hiroshi, D., Sasano, H., Nagura, H., Ogawa, N., and Hoffman, R. M. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res., 1: 1537-1543, 1995.
15. Ellis, W. J., Vessella, R. L., Buhler, K. R., Bladou, F., True, L. D., Bigler, S. A., Curtis, D., and Lange, P. H. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res., 2: 1039-1048, 1996.
16. van Weerden, W. M., de Ridder, C. M. A., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T. H., Schröder, F. H., and van Steenbrugge, G. J. Animal model: development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol., 149: 1055-1062, 1996.
17. Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., and Pretlow, T. P. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst., 85: 394-398, 1993.
18. Wainstein, M. A., He, F., Robinson, D., Kung, H-J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., Resnick, M. I., Seftel, A., and Pretlow, T. G. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049-6052, 1994.
19. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H-J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
20. Roth, B. J., Yeap, B. Y., Wilding, G., Kasimis, B., McLeod, D., and Loehrer, P. J. Taxol in advanced, hormone-refractory carcinoma of the prostate, A phase II trial of the Eastern Cooperative Oncology Group. Cancer (Phila.), 72: 2457-2460, 1993.
21. Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R., Gomella, L., Stem, C., and McAleer, C. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol., 22 (Suppl. 12): 41-45, 1995.
22. Chen, C. T., Au, J. L-S., Gan, Y., and Wientjes, M. G. Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumors. Urol. Oncol., 3: 11-17, 1997.
23. Chen, C. T., Au, J. L-S., and Wientjes, M. G. Pharmacodynamics of doxorubicin in human prostate tumors. Clin. Cancer Res., in press, 1997.
24. Jachez, B., Nordmann, R., and Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst., 85: 478-483, 1993.
25. Germann, U. A., Pastan, I., and Gottesman, M. M. P-glycoproteins: mediators of multidrug resistance. Semin. Cell Biol., 4: 63-76, 1993.
26. Chen, G., Jaffrezou, J. P., Fleming, W. H., Duran, G. E., and Sikic, B. I. Prevalence of multidrug resistance related to activation of the mdrl gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res., 54: 4980-4987, 1994.
27. Hale, A. J., Smith, C. A., Sutherland, L. C., Stoneman, V. E., Longthorne, V. L., Culhane, A. C., and Williams, G. T. Apoptosis: molecular regulation of cell death. Eur. J. Biochem., 236: 1-26, 1996.
28. Doering, C. H., Kraemer, H. C., Brodie, H. K., and Hamburg, D. A. A cycle of plasma testosterone in the human male. J. Clin. Endocrinol. Metab., 40: 492-500, 1975.
29. Wientjes, M. G., Pretlow, T. G., Badalament, R. A., Burgers, J. K., and Au, J. L-S. Histocultures of human prostate tissues for pharmacologic evaluation. J. Urol., 153: 1299-1302, 1995.
30. Gan, Y., Wientjes, M. G., Schuller, D. E., and Au, J. L-S. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res., 56: 2086-2093, 1996.
31. Reiss, M., Brash, D. E., Munoz-Antonia, T., Simon, J. A., Ziegler, A., Vellucci, V. F., and Zhou, Z. L. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol. Res., 4: 349-357, 1992.
32. Nathan, B., Gusterson, B., Jadayel, D., O'Hare, M., Anbazhagan, R., Jayatilake, H., Ebbs, S., Micklem, K., Price, K., Gelber, R., Reed R., Senn, H.-J., Goldhirsch, A., and Dyer, M. J. S. Expression of Bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann. Oncol., 5: 409-414, 1994.
33. Pretlow, T. G., Pelley, R. J., and Pretlow, T. P. Biochemistry of prostatic carcinoma. In: T. G. Pretlow and T. P. Pretlow (eds.), Biochemical and Molecular Aspects of Selected Cancers, pp. 169-237. San Diego: Academic Press, 1994.
34. Nemoto, R., Uchida, K., Shimazui, T., Hattori, K., Koiso, K., and Harada, M. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. J. Urol., 141: 337-340, 1989.
35. Scrivner, D. L., Meyer, J. S., Rujanavech, N., Fathman, A., and Scully, T. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J. Urol., 146: 1034-1039, 1991.
36. Au, J. L-S., Li, D., Gan, Y., Gao, X., Johnson, A. L., Johnston, J., Millenbaugh, N. J., Jang, S. H., Kuh, H-J., Chen, C-T., and Wientjes, M. G. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res., in press, 1998.
37. Au, J. L-S., Panchal, N., Li, D., and Gan, Y. Apoptosis. A new pharmacodynamic endpoint. Pharmacol. Res., 14: 1659-1671, 1997.